DanDi Bioscience

https://www.news1.kr/articles/4846838 

This post has been translated from the original article dated 10/28/2022. 

HLB Science, a domestic bio company, announced on the 28th that it would introduce innovative infectious disease treatment technology to multinational pharmaceutical companies by participating in the 'BIO-Europe 2022' online event.

Bio Europe is a global event xxxwhere about 2,000 companies from about 60 countries participate each year to discuss technology exports and joint development.

At Bio Europe, HLB Science plans to introduce sepsis treatment and superbacterial antibiotic technology under development to major research institutes and global pharmaceutical companies, and to promote information exchange and partnership for technological cooperation.

'DD-S052P', a peptide-based new drug candidate currently being developed by HLB Science, is a treatment for septicemia and gram-negative superbacterial infections with a dual mechanism that not only removes the causative bacteria but also neutralizes endotoxin, which is pointed out as a limitation of existing treatments.

DD-S052P received approval for phase 1 clinical trial plan (IND) from the French Ministry of Food and Drug Safety (ANSM) in July, and has now confirmed its safety, tolerability and blood pharmacokinetics in 72 healthy subjects at 'Eurofins Optimed' in France. are preparing for clinical trials.

Yoon Jong-seon, CEO of HLB Science, said, "DD-S052P is a low-toxic synthetic peptide material with a dual mechanism, and presents a new paradigm for sepsis treatment for which there is no suitable treatment yet. We will work closely with global partners with high competence in this field to develop multinational We will expand clinical trials on a global basis.”